Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04887805
Title Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

pancreatic ductal adenocarcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.